AbbVie: Pharmacyclics Acquisition ‘Deals a Huge Blow’ to Bears
March 06, 2015 at 13:51 PM EST
Jefferies analyst Jeffrey Holford and team explain why the acquisition of Pharmacyclics (PCYC) “marks an inflection point” for AbbVie (ABBV): Sipa USA/Associated Press The Pharmacyclics acquisition marks an inflection point for AbbVie. We believe that the company can achieve their peak revenue goal of more than $7bn for Imbruvica. Our modeling implies EPS accretion of 19c in [...]
